Evidence map›Paper›PMID 37131713›Full record

ArticlebioRxiv : the preprint server for biology2023

Jennifer E Wu, Sasikanth Manne, Shin Foong Ngiow, Amy E Baxter, Hua Huang, Elizabeth Freilich, Megan L Clark, Joanna H Lee, Zeyu Chen, Omar Khan and 5 more

Open access · greenAbstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in bioRxiv : the preprint server for biology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 4 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

15 authors at 4 institutions in 1 country.

Jennifer E WuDepartment of Systems Pharmacology and Translational Therapeutics, Perelman School of Medicine, University of Pennsylvania; Philadelphia, PA, USA.
Sasikanth ManneDepartment of Systems Pharmacology and Translational Therapeutics, Perelman School of Medicine, University of Pennsylvania; Philadelphia, PA, USA.
Shin Foong NgiowDepartment of Systems Pharmacology and Translational Therapeutics, Perelman School of Medicine, University of Pennsylvania; Philadelphia, PA, USA.
Amy E BaxterDepartment of Systems Pharmacology and Translational Therapeutics, Perelman School of Medicine, University of Pennsylvania; Philadelphia, PA, USA.
Hua HuangDepartment of Systems Pharmacology and Translational Therapeutics, Perelman School of Medicine, University of Pennsylvania; Philadelphia, PA, USA.
Elizabeth FreilichDepartment of Cancer Biology, Perelman School of Medicine, University of Pennsylvania; Philadelphia, PA, USA.
Megan L ClarkInstitute for Immunology and Immune Health, Perelman School of Medicine, University of Pennsylvania; Philadelphia, PA, USA.
Joanna H LeeDepartment of Systems Pharmacology and Translational Therapeutics, Perelman School of Medicine, University of Pennsylvania; Philadelphia, PA, USA.
Zeyu ChenDepartment of Systems Pharmacology and Translational Therapeutics, Perelman School of Medicine, University of Pennsylvania; Philadelphia, PA, USA.
Omar KhanDepartment of Systems Pharmacology and Translational Therapeutics, Perelman School of Medicine, University of Pennsylvania; Philadelphia, PA, USA.
Ryan P StaupeDepartment of Systems Pharmacology and Translational Therapeutics, Perelman School of Medicine, University of Pennsylvania; Philadelphia, PA, USA.
Yinghui J HuangDepartment of Systems Pharmacology and Translational Therapeutics, Perelman School of Medicine, University of Pennsylvania; Philadelphia, PA, USA.
Junwei ShiInstitute for Immunology and Immune Health, Perelman School of Medicine, University of Pennsylvania; Philadelphia, PA, USA.
Josephine R GilesDepartment of Systems Pharmacology and Translational Therapeutics, Perelman School of Medicine, University of Pennsylvania; Philadelphia, PA, USA.
E John WherryDepartment of Systems Pharmacology and Translational Therapeutics, Perelman School of Medicine, University of Pennsylvania; Philadelphia, PA, USA.
Parker Institute for Cancer Immunotherapy · USMerck & Co., Inc., Rahway, NJ, USA (United States) · USTranslational Therapeutics (United States) · USUniversity of California, San Francisco · US

Funding

Virology CoreU19AI082630 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI GEORG Michael LAUER · 2009 to 2026
$48.1M
Synergies among inhibitory receptors in tolerance, cancer & antiviral immunityP01AI108545 · NIAID · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI E. John Wherry · 2015 to 2026
$30.8M
IMMUNOBIOLOGY OF NORMAL AND NEOPLASTIC LYMPHOCYTEST32CA009140 · NCI · UNIVERSITY OF PENNSYLVANIA · PI Malay Haldar, WARREN S PEAR · 1985 to 2026
$16.1M
Sequencing and Viral Evolution CoreU19AI117950 · NIAID · UNIVERSITY OF PENNSYLVANIA · PI RILEY, JAMES L. · 2015 to 2019
$12.0M
Radiation and checkpoint blockade for cancer immune therapyP01CA210944 · NCI · UNIVERSITY OF PENNSYLVANIA · PI MAITY, AMIT, MINN, ANDY J · 2017 to 2022
$11.5M
HEMATOPOIESIS TRAINING GRANTT32DK007780 · NIDDK · UNIVERSITY OF PENNSYLVANIA · PI TONG, WEI · 1999 to 2023
$6.7M
TRAINING PROGRAM/RHEUMATIC DISEASEST32AR007442 · NIAMS · UNIVERSITY OF PENNSYLVANIA · PI BEHRENS, EDWARD M, MERKEL, PETER A · 1986 to 2018
$5.8M
Testing the role of BATF as a pioneer transcription factor in effector T cellsR01AI115712 · NIAID · DANA-FARBER CANCER INST · PI KADOCH, CIGALL, WHERRY, E. JOHN · 2015 to 2019
$2.9M
Temporal control of differentiation and epigenetics of Exhausted CD8 T cells by ToxR01AI155577 · NIAID · UNIVERSITY OF PENNSYLVANIA · PI WHERRY, E. JOHN · 2020 to 2024
$2.7M
Investigating molecular mechanism of immune response during cancer progressionK00CA234842 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI CHEN, ZEYU · 2021 to 2024
$370k
The Role of Tox in Regulating T Cell ExhaustionF30AI129263 · NIAID · UNIVERSITY OF PENNSYLVANIA · PI KHAN, OMAR · 2017 to 2019
$90k
Investigating molecular mechanism of T cell exhaustion in chronic infection and tumor microenvironmentF99CA234842 · NCI · UNIVERSITY OF PENNSYLVANIA · PI CHEN, ZEYU · 2018 to 2019
$78k
NCI NIH HHS F99 CA234842NCI NIH HHS K00 CA234842NCI NIH HHS P01 CA210944NCI NIH HHS T32 CA009140NIAID NIH HHS F30 AI129263NIAID NIH HHS P01 AI108545NIAID NIH HHS R01 AI115712NIAID NIH HHS R01 AI155577NIAID NIH HHS U19 AI082630NIAID NIH HHS U19 AI117950NIAMS NIH HHS T32 AR007442NIDDK NIH HHS T32 DK007780
6 · The paper itself

Abstract

Identifying novel molecular mechanisms of exhausted CD8 T cells (T

Identifiers

PMID37131713
PMCPMC10153201
OpenAlexW4366580335

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.